Toumaz Signs Sensium Sports Licensing Agreement

    Embargoed Release: 07:00hrs Fri 4th July 2008

                               Nanoscience Inc.                                

                        ('Nanoscience' or 'the Group')                         

          Toumaz Signs Significant Licensing Agreement to Develop its          
                         Sensium(tm) Technology in Sport                          

Nanoscience, the specialist niche investor in emerging technologies with strong
commercial propositions for the healthcare and electronic sectors, is pleased
to announce that its wholly-owned subsidiary Toumaz Technology Limited
(`Toumaz'), has signed a new licensing agreement with a sports-focussed
business originating from the Far East (the `Partner'), to develop Toumaz's
Sensium(tm) brand globally by establishing its technology in the sports industry.
The agreement is initially worth £1.5 million; £500,000 net has just been
received with the remainder to be paid within the next six months, pending the
fulfilment of certain obligations by Toumaz.

Under the agreement, the Sensium(tm) will initially target the football and horse
racing fields where a development programme is currently underway; strong
relationships with contacts and potential clientele have been established and
preliminary discussions have commenced to develop the Sensium(tm) as a premium
professional sports product. In addition, Toumaz is cultivating independent
relationships in the rugby sports sector.

The Sensium(tm) is a low-cost, end-to-end solution that measures human key vital
signs such as ECG, body temperature, respiration rate and physical movement on
a continuous and real time basis using unobtrusive, small and light wearable
devices that links wirelessly to a comprehensive data management system. Under
the agreement, it is envisaged that the Sensium(tm) will at first be developed as
a training aid with the aim of building a substantial and detailed data bank,
which would become an essential tool to support sports professionals and their
trainers.

The agreement highlights the adaptability of Toumaz's Sensium(tm) technology; it
has made impressive headway in the healthcare sector as relationships and
strategic partnership agreements have been signed with Texas Instruments
Incorporated and Cardinal Health to develop and market Sensium(tm) branded
products that are currently undergoing rigorous market testing and FDA approval
processes.

Guy Spelman, chief executive officer at Nanoscience, commented:

`The new licensing agreement represents an exciting opportunity for Toumaz and
its increasingly recognised Sensium(tm) technology. We believe the Sensium(tm) is the
ideal training aid to optimise the latent talent of sports professionals by
monitoring their health and fitness and capturing this data. Toumaz's new
Partner offers both extensive and well respected channels to the sports
industry and we at Nanoscience fully anticipate that the two parties working in
tandem will establish the Sensium(tm) as a formidable elite brand going forward.'

                                    -Ends-                                     

Further information:

Guy Spelman Nanoscience Inc. 07767 338 967

Tim Goodman Ambrian Partners 020 7634 4711

Vikki Krause Hansard Group 020 7245 1100

www.hansardgroup.co.uk

                                   - Ends -                                    

About Toumaz Technology (www.toumaz.com)

Toumaz Technology Limited is the leading provider of ultra-low power wireless
infrastructure for body monitoring solutions. Toumaz's ultra low-power smart
sensor interface and transceiver platform - the Sensium(tm) - enables
non-intrusive, real-time wireless monitoring of multiple vital signs for a wide
range of healthcare, sports and lifestyle management applications.

Based on Toumaz's patented ultra-low power Advanced Mixed Signal (`AMx(tm)')
technology, the Sensium(tm) provides the enabling technology to connect the mobile
individual to healthcare providers and sports trainers - simply, affordably and
unobtrusively.



END